In a recent social media post, Tandem Diabetes Care confirmed its t:slim X2 insulin pump will integrate with Abbott’s FreeStyle Libre 3 Plus sensor by the end of 2025. The collaboration marks a significant step toward expanding automated insulin delivery (AID) options for people with diabetes, combining Tandem’s Control-IQ+ (in the U.S.) technology with Abbott’s latest continuous glucose monitoring system.
According to Tandem, the integration will allow glucose readings from the Libre 3 Plus sensor to transmit automatically every minute to the t:slim X2 pump via Bluetooth. Users will be able to view data directly on the pump screen and within the Tandem t:slim mobile app. Control-IQ+ technology uses predictive algorithms to adjust insulin delivery based on glucose trends, helping reduce both high and low events.
The FreeStyle Libre 3 Plus sensor, currently the smallest patient-applied CGM in the world, offers 15-day sensor wear with accuracy supported by clinical data. Abbott reports that the extended wear time and compact design aim to reduce user burden while maintaining reliable performance. We recently reviewed the Libre 3 Plus after wearing it for one month.
This upcoming compatibility represents a new chapter in the AID landscape, which has largely relied on Dexcom sensors in commercial systems. The integration with Libre 3 Plus will make Tandem’s Control-IQ+ technology accessible to a broader range of users, offering additional flexibility for those who prefer Abbott’s CGM platform. Looking ahead, it’s likely we’ll see Libre 3 Plus support on Tandem Mobi, Tandem’s smaller tubed pump, though no official timeline has been confirmed.
We recently spoke with Tandem on the podcast about upcoming product integrations and the company’s roadmap for connected systems, and this update aligns with its focus on improving user choice within the AID ecosystem.
What are your thoughts on the t:slim X2 and Libre 3 Plus integration? Do you see this as an important step forward for diabetes tech?
Want more?
For the latest diabetes tech, join our free newsletter.
If you’re enjoying our content, consider joining Diabetech All Access—our premium membership with exclusive stories, Live Q&As, and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.